To assess the effectiveness of a SHort-course Accelerated RadiatiON therapy (SHARON) in the treatment of patients with multiple brain metastases.
T he prognosis of untreated patients with multiple brain metastases, poor performance status, and uncontrolled extracranial disease is estimated to be 1 month. Survival may be extended 2 months if dexamethasone is administered. 1 Radiotherapy (RT) is able to reduce the brain metastases size, especially in cases of lung and breast cancer, and to control symptoms in 70% to 90% of cases, with a reduction in the neurological-specific progression-ofdisease. 2 Moreover, the Radiation Therapy Oncology Group, using the recursive partitioning analysis (RPA), showed that RT combined with corticosteroid therapy improves overall survival (OS) (median 4.2 and 2.3 mo for RPA class 2 and 3, respectively). 3 For these reasons RT is currently a standard treatment for multiple brain metastases.
Afterwards, considering the heterogeneity of patients with brain metastases, a different prognostic index, the graded prognostic assessment (GPA), was developed aimed to identify significant diagnosis-specific prognostic factor in an updated era as compared with the previous RPA score. 4 The GPA was then refined based only on the statistically significant prognostic factors for each individual diagnosis. 5 The median OSs, not stratified for histology, of patients with GPA score of 0-1 or 1.5-2.0 was 3.1 and 5.4 months, respectively. 5, 6 Phase III studies by the Radiation Therapy Oncology Group (RTOG) have shown that short-course RT including 20 Gy in 5 fractions or 30 Gy in 10 fractions were as effective as more prolonged treatments in terms of frequency and duration of clinical improvement, time to disease progression, survival, and neurological symptoms relief, with less expense and inconvenience. 7, 8 On the basis of this evidence, the standard treatment was traditionally whole brain irradiation (WBRT) by 2 opposed-lateral fields with a total dose of 30 Gy in 10 fractions. 9 As palliative RT should achieve symptomatic relief with the shortest possible treatment, the efficacy of a more rapid fractionation scheme (10 Gy single fraction or 12 Gy in 2 fractions) was also investigated. 8, 10, 11 In addition, a study was conducted in our center to assess the tolerability of shortcourse accelerated RT in twice daily fractions for 2 consecutive days by a dose-escalation trail. 12 WBRT up to 18 Gy was well tolerated and preliminary results have shown a high rate of symptom remission with a good impact on quality of life (QoL). On the basis of these favorable results, the aim of this phase II study was to evaluate the efficacy on OS and symptom control.
MATERIALS AND METHODS

Study Design and End-points
A phase II study was designed to define the efficacy of short-course WBRT based on the dose level obtained from our earlier phase I experience. 12 Primary end-point was to better define the OS achievable with this treatment regimen. As the OS of patients treated with only supportive care has been shown to be around 2 months, 1 we designed the study to see if this fractionation scheme could achieve a survival at 2 months of 80%. This would represent an improvement from the 50% survival at 2 months that could be expected from best supportive care alone. A sample of 50 patients was estimated necessary to provide a statistically significant difference between 50% and 80%, with a test power of 80%.
Symptomatic progression-free survival (SPFS) was defined as the proportion of survival time spent in an improved or stable neurological state. Retreatment rate, acute and late toxicity, and QoL indices were defined as secondary end-points.
Eligibility Criteria
Patients were required to have pathologically (histologically or cytologically) proven diagnosis of solid malignancy advanced disease, defined as at least 3 brain metastases or metastatic disease in >3 organ systems. Eligible disease sites include: breast, prostate, gastrointestinal (colorectal, anal, esophagus, pancreas, gastric), head and neck, skin (melanoma and squamous cell carcinoma), lung (both small cell and nonsmall cell), sarcoma (both soft tissue and bone), and gynecologic (endometrial, cervical, ovarian, vaginal, vulvar). Other inclusion criteria were: ages more than 18 years, Eastern Cooperative Oncology Group (ECOG) performance status of r3, and no prior whole brain RT. RT between chemotherapy courses administration was not considered an exclusion criterion. At least a 10-day interval was required from the systemic treatment date. Pretreatment evaluation included a complete history, physical examination, complete blood count, and brain magnetic resonance imaging (MRI). Information on main neurological symptoms, ECOG performance status, and QoL was recorded at baseline and at each follow-up. An approximation was made that ECOG 0 or 1 was equivalent to Karnofsky performance status of Z70 and patients with a ECOG > 1 were considered as RPA class 3. 3 GPA score was also determined. 4 Pain was measured on the validated visual analogue self-assessment scale (VAS). 13 The QoL indexes were evaluated using cancer linear analog scales (CLAS) considering well-being (CLAS1), fatigue (CLAS2), and ability to perform daily activities (CLAS3). Patients scored their symptoms perceptions by placing a mark on a 100-mm line to indicate symptom magnitude. 14 
Treatment
All patients underwent computed tomography simulation in the supine position. A thermoplastic mask was used for accurate patient immobilization. The clinical target volume was defined as the whole brain. A margin of 1 cm in all directions was added for the planning target volume. Threedimensional conformal RT was planned using the Oncentra MasterPlan (Nucletron B.V., Veenendaal; the Netherlands) treatment planning system. Patients received 18 Gy (4.5 Gy/ fraction) of radiation. On the basis of the linear quadratic equation, considerations of expected late complications (a/b ratio: 3), the equivalent dose in 2 Gy fractions relative to the total dose prescribed was 27 Gy. 15 The dose was specified according to the ICRU Report 62. 16 Dose-volume histograms were calculated for the planning target volume and organs at risk. The treatment was delivered by an Elekta Precise Linac equipped with standard multileaf collimators. Patients were irradiated in 2 consecutive days with twice daily fractionation, with an interval of at least 8 hours. An adequate dose of steroids was administered. The dexamethasone prescribed dose was 4 mg twice daily during RT, and instructions for dose tapering over the 4 weeks following RT were given to each patient.
Toxicity and Response Evaluation
Three weeks after treatment, all patients underwent the first evaluation. Afterwards, patients were followed at 2-month intervals. Evaluation consisted of history, physical examination, and complete laboratory tests including a full blood count, blood electrolytes, and creatinine and liver transaminases. Acute and late radiation toxicities were scored according to the RTOG and the EORTC-RTOG scales, respectively. 17 Information on late sequelae concerning mental changes, dementia, weakened memory, and concentration was collected from patients and their caregivers. Detailed intelligence and personality tests were not performed. Indices related to symptomatic relief, pain, and QoL were recorded and compared with baseline values. Complete pain relief was defined as VAS score of 0. Symptom response was scored as follows: complete response (CR): complete symptoms resolution; partial response (PR): reduction but not resolution of symptoms severity; no change: stable symptoms severity; progression: symptoms worsening. 18 Restaging was performed 2 months after RT by a complete history, physical examination, complete blood count, and brain MRI. Clinical response was assessed according to the World Health Organization criteria 19 and determined by the proportion of patients achieving CR or PR. Patients were considered to have responded (CR + PR) if there was a Z50% decrease in lesion size and they were on a stable or decreasing dose of corticosteroids. Intracranial progression-free time was defined as the duration during which there was no intracranial metastases growth and no new brain metastases. 20 
Statistical Analysis
The statistical analysis was performed with SYSTAT, version 11.0 (SPSS, Chicago, IL). Wilcoxon signed rank test was used to compare QoL parameters before and after RT. OS and SPFS were calculated using the Kaplan-Meier method. 21 OS was calculated from the date of the RT to the date of death or date of last observation; SPFS was calculated from the date of RT by defining as event any symptoms relapse/progression or death from any cause, whichever came first. 22 
Ethical Considerations
All procedures were approved by the Internal Board Committee and the Institutional Ethic Committee, and were in accordance with the Helsinki Declaration, as revised in 2008. All patients provided written informed consent before study entry.
RESULTS
Patient Characteristics
Fifty patients were treated. Patient characteristics are detailed in Table 1 . The most frequent primary tumor sites were lung (48%) and breast (22%). Histopathology is detailed in Table 2 . Twenty-six patients (52%) showed >3 brain metastases at the time of diagnosis. Forty-six patients had extracranial site of metastases. Nineteen patients (38%) had ECOG performance status <1 and were considered as RPA class 3. In contrast, related to the other prognostic factor (age, number of brain metastases, and presence of extracranial disease), 42 patients (84%) had a GPA score of 0-1. Twentyseven patients had baseline neurological symptoms: headache and/or drowsiness plus sensorial clouding (70.4%) and ataxia and/or vertigo (25.9%) ( Table 3 ).
Symptom Relief and QoL
Three weeks after treatment, 17 of 27 symptomatic patients showed an improvement or resolution of baseline symptoms (overall palliative response rate: 63.0%; 95% confidence interval, 36.6%-82.4%). In detail, 9 patients (33.3%) had a complete palliative response, 8 patients (29.6%) were stable, and 2 patients (7.4%) had progressed. A significant reduction of headache, as evaluated by VAS, was recorded (pretreatment vs. posttreatment mean VAS: 3.0 ± 2.2 vs. 0.0.0 ± 2.9; P = 0.008). Eight patients (47%) had complete pain relief. The overall median duration of palliation in these patients was 7 months.
At the first follow-up, 7 patients (14%) had an improved ECOG performance status and 34 (68%) were stable. Twentyseven of 30 patients (60%) were able to rank the different aspects of QoL as well-being (CLAS1), fatigue (CLAS2), and ability to perform daily activities (CLAS3) using a VAS. A nonsignificant increase in the mean differences of all these indices has been recorded.
Local Control and Survival
Restaging was not possible in 16 of 50 patients (32%) because of patients' refusal or for practical reasons (mainly home care or hospice assistance). Nevertheless, restaging was performed in 32 patients (64%) by brain MRI. Sixteen patients (32%) were considered to be responders (CR = 1; PR = 15) and 12 patients had stable disease. Progression-of-disease was documented in 4 patients (8%) and 3 of these patients underwent retreatment with the same fractionation schedule to total dose of 12 Gy, without grade Z3 acute toxicity.
At the last observation 38 patients had died. In 4 and 6 of them, death was due to progression of brain metastases and systemic disease, respectively, whereas in 22 patients, the cause of death was not clearly defined. The median survival time was 7 months and 2-and 6-month OS were 86% and 51%, respectively ( Fig. 1) . Particularly, median OS in 20 patients with non-small cell lung cancer and in 11 patients with breast cancer were 6 and 8 months, respectively. Moreover, 6-month OS was improved in patients with r3 brain metastasis compared with those with >3 brain metastasis (66% vs. 35%; P = 0.019) and a trend of improved OS was observed in patients with better performance status (ECOGr1; P = 0.2).
Although no different OS was observed in symptomatic versus asymptomatic patients, the median SPFS of symptomatic patients was 5 months (Fig. 2 ).
Toxicity
The most common acute toxicity was grade 1 central nervous system (30%): headache in 7 patients (14%), mild drowsiness in 5 patients (10%), and nausea in 3 patients (6%). Eight patients (16%) had grade 2 neurological toxicity (drowsiness and/or headache) requiring increased steroids dose. Neurological impairment requiring hospitalization (grade 3 acute toxicity) developed in 3 patients. Grade 1 skin toxicity was observed in 9 patients (18%): temporary partial hair loss (alopecia) in 6 patients and erythema in 3 patients. Three patients (6%) had grade 2 acute skin toxicity (moderate erythema).
Forty-two patients (84%) received RT between systemic therapy courses. Acute hematologic toxicity (grade 1-2 anemia) was observed only in 3 patients (7.1%). Two patients died within 30 days after RT. These patients were symptomatic at treatment time and showed a progressive worsening of the clinical condition.
With a median follow-up time of 6 months (range, 1 to 18 mo), no late toxicities were observed, except for grade 1 late toxicities (partial hair loss) at 4 and 6 months in 2 patients. The need for steroids was documented in 6 of 26 (23%) long-term survivors ( > 6 mo) patients. Four of them had documented progression disease of brain metastases.
DISCUSSION
RT in the palliative setting should provide durable symptomatic relief while maintaining a good quality end-oflife. Therefore, the benefits of WBRT in brain metastases patients with poor performance status and extensive active extracranial disease have been questioned. In fact, as the poor prognosis of patients with multiple brain metastases (median survival time: 3 to 5 mo [3] [4] [5] ), a balance between treatment duration and intensity must be ascertained. 7 For these reasons, shortcourse RT may be useful in terms of less discomfort associated with waiting time for treatment, transportation, and costs. In contrast, accelerated RT may increase acute side effects and, consequently, lead to reduced survival or worsened QoL.
Although the use of higher dose fractions could be considered controversial, with worsening of higher late toxicity and cognitive functions, 23-25 some randomized trials have compared WBRT of 30 Gy in 10 fractions with short-course WBRT schedules concerning the OS (Table 4 ). Furthermore, the assessment of the impact on QoL by means of validated scales is lacking.
Referring to these randomized studies (Table 4 ), shortcourse RT was effective in terms of OS, showing a median survival time of 6.8 months and a 6-month OS rate of 50%. These results are particularly encouraging taking into account that the longest median survival time in those studies was 6.6 months, as shown in a patient population with good performance status (RPA class 1-2) treated with WBRT to 20 Gy/5 fractions 26 and that the 6-month OS rates after 20 Gy in 5 fractions was 29% in the retrospective study by Rades et al. 27 A previous phase I study was conducted in our center to assess the tolerability of short-course accelerated WBRT in twice daily fractions for 2 consecutive days by a dose-escalation trail up to 18 Gy. Grade 1 and 2 acute neurological (26.4%) and skin (18.3%) toxicities were recorded. Only 1 patient experienced DLT (neurological grade 3 acute toxicity). 12 On the basis of favorable results in terms of tolerability of this previous experience, the present study aimed to evaluate the efficacy of short-course accelerated WBRT to 18 Gy in twice daily fractions for 2 consecutive days. In our study, patients with solid malignancy from different primary sites and advanced disease (at least 3 brain metastases or metastatic disease in >3 organ systems) were enrolled.
Related to these inclusion criteria, all enrolled patients had a GPA score of 0-1 or 1.5-2.0. Median survivals, not stratified for histology, of patients with these scores was 3.1 and 5.4 months, respectively. [4] [5] [6] In our experience the median survival time was 7 months and 2-and 6-month OS were 86% and 51%, respectively ( Fig. 1) . Considering that 42 of 50 patients (84%) had GPA score of 0-1, this result could be considered interesting to provide a basis for planning future clinical investigations.
In addition, short-course WBRT was effective to prevent QoL deterioration and to relieve symptoms. Twenty-seven of 30 patients (60%) were able to rank the different aspects of QoL as well-being (CLAS1), fatigue (CLAS2) and ability to perform daily activities (CLAS3) using a VAS. A nonsignificant increase in the mean differences of all these indices has been recorded. Moreover, 41 patients (72%) had an improved or stable ECOG performance status. As the ECOG performance status is an index of functional independence and indirectly a QoL parameter, these results were considered relevant. Furthermore, an improvement or resolution of baseline symptoms in 17 of 27 symptomatic patients (overall palliative response rate: 63.0%; 95% confidence interval, 36.6%-82.4%). In detail, 9 patients (33.3%) had a complete palliative response and 8 patients (47%) had complete pain relief. Overall, the median SPFS was 5 months.
At least, the treatment showed a good toxicity profile. Only, 3 patients (6%) experienced neurological grade 3 acute toxicity. Moreover, the incidence of late toxicity was particularly low (prolonged alopecia was observed in 1 patient), as expected according to the linear quadratic model. In fact, using an a/b ratio of 3, the dose level used in this trial is equivalent for late responders tissues to a dose of 27 Gy (with fractions of 2 Gy). 15 To the best of our knowledge, our study was the first to test a regimen of 4 fractions in 2 days in the treatment of brain metastases. The results indicate the possibility to deliver a relatively high dose without relevant acute and late toxicity, similar to that shown for other tumors in other body areas. In fact, a similar regimen was used in advanced pelvic tumors 28, 29 at total dose of 18 Gy, and in head and neck tumors 30 with total dose of 14 Gy.
However, this study includes some limitations. A statistically significant stratification of the outcomes in relation to the RPA classes, GPA score, and primary tumor histology was not possible to obtain, because of the trial design as well as to the number of enrolled patients. Furthermore, only 60% of patients were able to rank QoL parameters using a VAS. A randomized trial comparing this schedule with a more traditional palliative regimen (30 Gy in 10 fractions) will be probably useful to confirm the effectiveness of this schedule in terms of prognostic index, performance status, and QoL by a large number of enrolled patients.
In conclusion, on the basis of the documented tolerability of short-course accelerated WBRT to 18 Gy in twice daily fractions for 2 consecutive days in terms of late toxicity and on the efficacy in OS and symptoms response rate, this treatment could be particularly useful in daily practice for patients with difficulties in transfers to the RT center and for departments with waiting list problems. However, caution is advised for widespread adoption of this schedule of treatment until further investigation. Finally, based on all previous considerations a phase III trial was planned to compare this scheme with 30 Gy in 10 fractions. 
